Lantheus (NASDAQ:LNTH) Rating Increased to Strong-Buy at Wall Street Zen

Lantheus (NASDAQ:LNTH) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

LNTH has been the subject of several other reports. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Tuesday, February 24th. Citizens Jmp upped their target price on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research report on Tuesday, February 24th. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. William Blair reissued an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Finally, Truist Financial upped their price objective on shares of Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a report on Friday, February 27th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.14.

Lantheus Stock Down 2.5%

Shares of NASDAQ LNTH opened at $74.47 on Friday. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $4.85 billion, a PE ratio of 22.10 and a beta of -0.11. The stock’s fifty day simple moving average is $72.49 and its two-hundred day simple moving average is $63.27. Lantheus has a 12-month low of $47.25 and a 12-month high of $108.91.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. The business had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The firm’s revenue was up 4.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts expect that Lantheus will post 6.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LNTH. Elevation Point Wealth Partners LLC acquired a new stake in shares of Lantheus in the second quarter valued at approximately $26,000. Osterweis Capital Management Inc. acquired a new position in Lantheus during the second quarter worth $36,000. Hantz Financial Services Inc. grew its holdings in Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares in the last quarter. First Horizon Corp purchased a new stake in Lantheus in the 3rd quarter valued at $26,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 197 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.